Mesoblast Chief Medical Officer Dr Fred Grossman said: “There is an urgent need for targeted treatments to reduce the continued high mortality in COVID-19 ARDS patients who are dependent on mechanical ventilators. We expect to complete the enrollment target in this important trial by the end of the year as the enrollment rate continues to increase in line with the surge in new infections across the United States.”
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-6
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.29 |
Change
-0.020(0.87%) |
Mkt cap ! $2.918B | |||
| Open | High | Low | Value | Volume |
| $2.32 | $2.39 | $2.24 | $11.38M | 4.926M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 81271 | $2.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.29 | 35730 | 52 |
View Market Depth
| Last trade - 15.24pm 22/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |